News tagged with docetaxel
Related topics: breast cancer , chemotherapy , prostate cancer , cancer drugs
Liver metastases and its prognostic significance in men with metastatic prostate cancer
Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in ...
Cancer
May 31, 2012 |
not rated yet |
0
Cabazitaxel can offer an advantage in certain patients
Cabazitaxel (trade name: Jevtana) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic ...
Cancer
May 29, 2012 |
not rated yet |
0
Biomarker family found for chemo resistant breast cancers
Biomarkers which could help to predict resistance to chemotherapy in breast cancer patients have been identified by researchers from the University of Hull, UK.
Cancer
Apr 12, 2012 |
5 / 5 (1) |
0
New cancer drug delivery system shows promise
A new method of delivering cancer drugs that could cut down on chemotherapy's side effects and boost the strength of the tumor-fighting medicine has shown promise, US researchers said Wednesday.
Cancer
Apr 04, 2012 |
not rated yet |
0
BIND presents late-breaker clinical data at AACR on BIND-014's promising antitumor effects
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, ...
Cancer
Apr 04, 2012 |
not rated yet |
0
Bevacizumab doesn't up overall survival in prostate cancer
(HealthDay) -- For men with metastatic castration-resistant prostate cancer (mCRPC), the addition of bevacizumab (B) to docetaxel plus prednisone (DP) is not associated with improved overall survival (OS), ...
Cancer
Mar 27, 2012 |
not rated yet |
0
Ganetespib showed activity in KRAS-mutant NSCLC as monotherapy and in combinations
The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active ...
Cancer
Jan 11, 2012 |
not rated yet |
0
Abiraterone: Indication of considerable added benefit in certain patients
Abiraterone (trade name: Zytiga) has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic ...
Medications
Jan 06, 2012 |
not rated yet |
0
Addition of bevacizumab to conventional therapy improved progression-free survival in HER2-positive breast cancer
Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from ...
Cancer
Dec 08, 2011 |
not rated yet |
0
Dual HER2 blockade significantly extends progression-free survival
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who ...
Cancer
Dec 08, 2011 |
not rated yet |
0
Abiraterone acetate improves fatigue in prostate cancer patients, says international clinical trial
Stockholm, Sweden: Men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone, ...
Cancer
Sep 25, 2011 |
not rated yet |
0
Drug shown to significantly improve survival in men with metastatic prostate cancer
The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with ...
Cancer
Jun 06, 2011 |
not rated yet |
0
Abcc10 may be effective in extending the effectiveness of anticancer drugs
Today's anticancer drugs often work wonders against malignancies, but sometimes tumors become resistant to the effects of such drugs, and treatment fails. Medical researchers would like to find ways of counteracting such ...
Cancer
May 16, 2011 |
5 / 5 (1) |
0
|
Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival ...
Cancer
Apr 21, 2011 |
not rated yet |
0
- Pages: 1 2
